Related Experiment Video
Updated: Jan 29, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Detection of androgen receptor (AR) and AR-V7 in small cell prostate carcinoma: Diagnostic and therapeutic
Pei Zhao1, Yezi Zhu1, Liang Cheng2
1Department of Urology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Objective:
Small cell prostate carcinoma (SCPC) is a rare and highly malignant subtype of prostate cancer. SCPC frequently lacks androgen receptor (AR) and prostate-specific antigen (PSA) expression, and often responds poorly to androgen deprivation therapy (ADT). AR splice variant-7 (AR-V7) is a truncated AR protein implicated in resistance to AR-targeting therapies. AR-V7 expression in castration-resistant prostate cancers has been evaluated extensively, and blood-based detection of AR-V7 has been associated with lack of response to abiraterone and enzalutamide. However, whether AR-V7 is expressed in SCPC is not known.
Methods:
Using validated antibodies, we performed immunohistochemistry (IHC) assay for the full-length AR (AR-FL) and (AR-V7) on post-ADT surgical SCPC specimens.
Results:
Seventy-five percent (9/12) of the specimens showed positive staining for the AR-FL with various intensities. Thirty-three percent (4/12) of the specimens showed positive staining for AR-V7. Among the specimens with positive AR-V7 staining, two samples displayed very weak staining, one sample showed weak-to-moderate staining, and one sample showed strong staining. All positive specimens displayed a heterogeneous pattern of AR-FL/AR-V7 staining. All specimens positive for AR-V7 were also positive for AR-FL.
Conclusion:
The study findings support the existence of measurable AR-FL and AR-V7 proteins in SCPC specimens. The results also have implications in detection of AR-V7 in specimens obtained through systemic sampling approaches such as circulating tumor cells. A positive AR-V7 finding by blood-based tests is not impossible in patients with SCPC who often demonstrate low PSA values.
Insights
Small cell prostate carcinoma (SCPC) can express androgen receptor (AR) and the AR splice variant-7 (AR-V7) protein. This finding is significant for understanding treatment resistance in SCPC patients, even with low prostate-specific antigen (PSA) levels.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Small cell prostate carcinoma (SCPC) is a rare, aggressive cancer.
- SCPC often lacks androgen receptor (AR) and prostate-specific antigen (PSA) expression.
- AR splice variant-7 (AR-V7) is linked to resistance to AR-targeting therapies.
Purpose of the Study:
- To investigate the expression of AR and AR-V7 in SCPC.
- To determine if AR-V7 is present in SCPC, a factor in treatment resistance.
Main Methods:
- Immunohistochemistry (IHC) was used to detect AR-FL and AR-V7.
- Validated antibodies were employed on post-androgen deprivation therapy (ADT) SCPC specimens.
Main Results:
- 75% of SCPC specimens expressed full-length AR (AR-FL).
- 33% of SCPC specimens showed positive staining for AR-V7.
- AR-V7 expression was heterogeneous and always co-occurred with AR-FL.
Conclusions:
- Measurable levels of AR-FL and AR-V7 proteins exist in SCPC.
- AR-V7 detection in circulating tumor cells may be possible in SCPC.
- Positive AR-V7 blood tests are feasible in SCPC patients, despite low PSA.
More Related Videos
Related Concept Videos
Internal Receptors
Types of Receptors: Cell Surface Receptors
Therapeutic Index
Receptor-mediated Endocytosis
Enzyme-linked Receptors
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
G-protein Coupled Receptors

